CS
ARQT icon

Credit Suisse’s Arcutis Biotherapeutics ARQT Stock Holding History

Credit Suisse’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,500
Closed -$609K – 4493
2021
Q3 		$609K Buy
+25,500
New +$582K ﹤0.01% 3682

Other funds holding ARQT

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Credit Suisse's ARQT Position: Q4 2023 in Review

Credit Suisse sold out of Arcutis Biotherapeutics (ARQT) in Q4 2023, closing a stake of 57,477 shares — an estimated $305K sold.

Credit Suisse first reported a position in ARQT in Q4 2020 and held it in 12 quarters. The position peaked at $746K in Q2 2023. 133 funds tracked by Wall St. Rank hold ARQT as of Q4 2023.

  • Credit Suisse reported no remaining Arcutis Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 57,477 Arcutis Biotherapeutics shares in Q4 2023, an estimated $305K.
  • Credit Suisse first reported a position in Arcutis Biotherapeutics in Q4 2020 and held it in 12 quarters.
  • Credit Suisse's Arcutis Biotherapeutics position peaked at $746K in Q2 2023.
  • 133 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.